Cingulate Inc (CING) - News Archive

In a significant development for Cingulate Inc. (NASDAQ: CING), a Kansas City-based biopharmaceutical company specialized in innovative drug delivery platforms, Shane J. Schaffer, Chairman and CEO, recently participated...

In a significant development, Cingulate Inc., a Kansas City-based biopharmaceutical company, has recently announced the immediate exercise of a substantial number of Series A and Series B warrants, leading to gross proc...

KANSAS CITY, Kan., Feb. 06, 2024 - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) recently announced the successful completion of its public offering, marking a significant milestone in the advancement of its p...

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketKansas City, Kan. - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) has recently...

IntroductionCingulate Inc., a biopharmaceutical company focused on developing next-generation pharmaceutical products, has announced receiving guidance from the Food and Drug Administration (FDA) on moving forward with...

Kansas City-based biopharmaceutical company, Cingulate Inc. (NASDAQ: CING), has recently announced the pricing of its public offering, which is expected to raise a total of $4.0 million. These funds will be utilized to...